Contact
searchSearch
HMP Global
Login

Colorectal Cancer Specialty Channel

Colorectal Cancer
Specialty Channel
News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
News
Adding Sintilimab to Neoadjuvant Short-Course Radiotherapy Plus Chemotherapy for Newly Diagnosed Patients With Locally Advanced Rectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the...
08/26/2025
Oncology
News
Efficacy, Safety of Various Total Neoadjuvant Therapy Approaches Among Patients With Locally Advanced Rectal Cancer
08/12/2025
Stephanie Holland
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case...
08/12/2025
Oncology
News
Avelumab Following Long-Course Chemoradiotherapy Demonstrates Clinical Promise Among Patients With Locally Advanced, Resectable Rectal Cancer
08/05/2025
Stephanie Holland
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the...
08/05/2025
Oncology
Quiz
Atezolizumab Plus mFOLFOX for Patients With Mismatch Repair Deficient Colon Cancer
07/29/2025
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the...
07/29/2025
Oncology
Conference Coverage
Circulating Tumor DNA Methylation-Guided Postoperative Surveillance For Patients With Non-Metastatic Colorectal Cancer
07/08/2025
Allison Casey
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis...
07/08/2025
Oncology
News
Lean Body Mass-Based Dose Adjustments Significantly Reduces the Rate of Oxaliplatin-Induced Peripheral Neurotoxicity in Colon Cancer
07/01/2025
Stephanie Holland
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX...
07/01/2025
Oncology
Conference Coverage
Liquid Biopsy-Guided Anti-EGFR Retreatment Improves Survival and Response Rates in Metastatic Colorectal Cancer
06/01/2025
Emily Estrada
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial...
06/01/2025
Oncology
Conference Coverage
Atezolizumab Added to Chemotherapy Significantly Improves Survival in Deficient Mismatch Repair Colon Cancer
06/01/2025
Emily Estrada
Findings from the phase 3 ATOMIC tria show the addition of atezolizumab to standard chemotherapy improved survival outcomes for patients with resected stage III deficient mismatch repair colon cancer.
Findings from the phase 3 ATOMIC tria show the addition of atezolizumab to standard chemotherapy improved survival outcomes for patients with resected stage III deficient mismatch repair colon cancer.
Findings from the phase 3 ATOMIC...
06/01/2025
Oncology
Conference Coverage
Anlotinib vs Bevacizumab Added to First-Line Chemotherapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
05/31/2025
Emily Estrada
For the treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer without any prior lines of treatment, anlotinib demonstrated similar efficacy and safety to bevacizumab in a phase 3 clinical trial.
For the treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer without any prior lines of treatment, anlotinib demonstrated similar efficacy and safety to bevacizumab in a phase 3 clinical trial.
For the treatment of...
05/31/2025
Oncology
News
Nivolumab Plus Relatlimab for Patients With Unresectable or Metastatic Mismatch Repair Proficient Colorectal Cancer
05/22/2025
Stephanie Holland
Results from a phase 2 study identified the effect that treatment with nivolumab and relatlimab has on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Results from a phase 2 study identified the effect that treatment with nivolumab and relatlimab has on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Results from a phase 2 study...
05/22/2025
Oncology

News

News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
News
Adding Sintilimab to Neoadjuvant Short-Course Radiotherapy Plus Chemotherapy for Newly Diagnosed Patients With Locally Advanced Rectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the...
08/26/2025
Oncology
News
Efficacy, Safety of Various Total Neoadjuvant Therapy Approaches Among Patients With Locally Advanced Rectal Cancer
08/12/2025
Stephanie Holland
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case...
08/12/2025
Oncology
News
Avelumab Following Long-Course Chemoradiotherapy Demonstrates Clinical Promise Among Patients With Locally Advanced, Resectable Rectal Cancer
08/05/2025
Stephanie Holland
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the...
08/05/2025
Oncology
Conference Coverage
Circulating Tumor DNA Methylation-Guided Postoperative Surveillance For Patients With Non-Metastatic Colorectal Cancer
07/08/2025
Allison Casey
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis...
07/08/2025
Oncology
News
Lean Body Mass-Based Dose Adjustments Significantly Reduces the Rate of Oxaliplatin-Induced Peripheral Neurotoxicity in Colon Cancer
07/01/2025
Stephanie Holland
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX...
07/01/2025
Oncology
Conference Coverage
Liquid Biopsy-Guided Anti-EGFR Retreatment Improves Survival and Response Rates in Metastatic Colorectal Cancer
06/01/2025
Emily Estrada
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial...
06/01/2025
Oncology
Conference Coverage
Atezolizumab Added to Chemotherapy Significantly Improves Survival in Deficient Mismatch Repair Colon Cancer
06/01/2025
Emily Estrada
Findings from the phase 3 ATOMIC tria show the addition of atezolizumab to standard chemotherapy improved survival outcomes for patients with resected stage III deficient mismatch repair colon cancer.
Findings from the phase 3 ATOMIC tria show the addition of atezolizumab to standard chemotherapy improved survival outcomes for patients with resected stage III deficient mismatch repair colon cancer.
Findings from the phase 3 ATOMIC...
06/01/2025
Oncology
Conference Coverage
Anlotinib vs Bevacizumab Added to First-Line Chemotherapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
05/31/2025
Emily Estrada
For the treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer without any prior lines of treatment, anlotinib demonstrated similar efficacy and safety to bevacizumab in a phase 3 clinical trial.
For the treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer without any prior lines of treatment, anlotinib demonstrated similar efficacy and safety to bevacizumab in a phase 3 clinical trial.
For the treatment of...
05/31/2025
Oncology
News
Nivolumab Plus Relatlimab for Patients With Unresectable or Metastatic Mismatch Repair Proficient Colorectal Cancer
05/22/2025
Stephanie Holland
Results from a phase 2 study identified the effect that treatment with nivolumab and relatlimab has on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Results from a phase 2 study identified the effect that treatment with nivolumab and relatlimab has on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Results from a phase 2 study...
05/22/2025
Oncology

Interactive Features

Quiz
Atezolizumab Plus mFOLFOX for Patients With Mismatch Repair Deficient Colon Cancer
07/29/2025
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the...
07/29/2025
Oncology
Quiz
Quiz: Incidence of Anal Cancer
05/18/2023
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has...
05/18/2023
Oncology
Test Your Knowledge
Quiz: Does Pembrolizumab Plus CRT After FOLFOX Provide Benefit for LARC?
09/03/2021
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the...
09/03/2021
Oncology
Quiz
Quiz: Which Therapy Enhances Tumor Immunologic Response in LARC?
08/09/2021
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer
04/22/2021
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a...
04/22/2021
Oncology
Test Your Knowledge
Quiz: Does Coffee Consumption Yield Benefit in CRC?
04/05/2021
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds...
04/05/2021
Oncology
Test Your Knowledge
Quiz: What Are the 3 Current Modalities for Rectal Cancer?
03/24/2021
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3...
03/24/2021
Oncology
Test Your Knowledge
Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology

Recent News

News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
News
Adding Sintilimab to Neoadjuvant Short-Course Radiotherapy Plus Chemotherapy for Newly Diagnosed Patients With Locally Advanced Rectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the phase 2 SPRING-01 trial, adding sintilimab to neoadjuvant short-course radiotherapy plus chemotherapy significantly improved pathological complete response among newly diagnosed patients with locally advanced...
According to results from the...
08/26/2025
Oncology
News
Efficacy, Safety of Various Total Neoadjuvant Therapy Approaches Among Patients With Locally Advanced Rectal Cancer
08/12/2025
Stephanie Holland
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer.
According to results from a case...
08/12/2025
Oncology
News
Avelumab Following Long-Course Chemoradiotherapy Demonstrates Clinical Promise Among Patients With Locally Advanced, Resectable Rectal Cancer
08/05/2025
Stephanie Holland
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the phase 2 Ave-Rec trial, avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer.
According to results from the...
08/05/2025
Oncology
News
Lean Body Mass-Based Dose Adjustments Significantly Reduces the Rate of Oxaliplatin-Induced Peripheral Neurotoxicity in Colon Cancer
07/01/2025
Stephanie Holland
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX trial demonstrated that using lean body mass to adjust oxaliplatin dosage significantly reduces the rate of oxaliplatin-induced peripheral neurotoxicity among patients with stage 3 colon cancer.
Results from the phase 2 LEANOX...
07/01/2025
Oncology
Conference Coverage
Liquid Biopsy-Guided Anti-EGFR Retreatment Improves Survival and Response Rates in Metastatic Colorectal Cancer
06/01/2025
Emily Estrada
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial demonstrated an overall response rate and progression-free survival advantage with liquid biopsy-guided anti-EGFR retreatment vs regorafenib for chemorefractory metastatic colorectal cancer with RAS and BRAF wild-type...
The phase 2 PARERE trial...
06/01/2025
Oncology
Conference Coverage
Atezolizumab Added to Chemotherapy Significantly Improves Survival in Deficient Mismatch Repair Colon Cancer
06/01/2025
Emily Estrada
Findings from the phase 3 ATOMIC tria show the addition of atezolizumab to standard chemotherapy improved survival outcomes for patients with resected stage III deficient mismatch repair colon cancer.
Findings from the phase 3 ATOMIC tria show the addition of atezolizumab to standard chemotherapy improved survival outcomes for patients with resected stage III deficient mismatch repair colon cancer.
Findings from the phase 3 ATOMIC...
06/01/2025
Oncology
Conference Coverage
Anlotinib vs Bevacizumab Added to First-Line Chemotherapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
05/31/2025
Emily Estrada
For the treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer without any prior lines of treatment, anlotinib demonstrated similar efficacy and safety to bevacizumab in a phase 3 clinical trial.
For the treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer without any prior lines of treatment, anlotinib demonstrated similar efficacy and safety to bevacizumab in a phase 3 clinical trial.
For the treatment of...
05/31/2025
Oncology
News
Nivolumab Plus Relatlimab for Patients With Unresectable or Metastatic Mismatch Repair Proficient Colorectal Cancer
05/22/2025
Stephanie Holland
Results from a phase 2 study identified the effect that treatment with nivolumab and relatlimab has on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Results from a phase 2 study identified the effect that treatment with nivolumab and relatlimab has on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
Results from a phase 2 study...
05/22/2025
Oncology
News
Impact of Relative Dose Intensity of Chemotherapy on Clinical Outcomes in Metastatic Colorectal Cancer
05/21/2025
Stephanie Holland
Pooled analysis results from the phase 3 TRIBE and TRIBE2 studies suggest that a higher relative dose intensity of first-line FOLFOXIRI or FOLFOX/FOLFIRI plus bevacizumab improves outcomes among patients with metastatic colorectal cancer.
Pooled analysis results from the phase 3 TRIBE and TRIBE2 studies suggest that a higher relative dose intensity of first-line FOLFOXIRI or FOLFOX/FOLFIRI plus bevacizumab improves outcomes among patients with metastatic colorectal cancer.
Pooled analysis results from the...
05/21/2025
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use